Page 1

EX - 99.1 2 d374028dex991.htm EX - 99.1 Igm biosciences ™ IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update - Recommended Phase 2 Dose of IGM - 2323 Expected in 2021 – - Initial Data from Phase 1 Trial of IGM - 8444 in Solid Cancers Expected in 2021 – - Expansion of IgM Platform into Infectious Diseases - MOUNTAIN VIEW , Calif . , August 9 , 2021 - IGM Biosciences , Inc. ( Nasdaq : IGMS ) , a clinical - stage biotechnology company focused on creating and developing engineered IgM antibodies , today announced its financial results for the second quarter ended June 30 , 2021 and provided an update on recent developments . Pipeline Updates IGM - 2323 IGM - 8444 Exhibit 99.1 " We continue to make steady progress in the development of our innovative product pipeline , including the successful completion of the initial dose escalation portion of our IGM - 2323 Phase 1 clinical trial , " said Fred Schwarzer , Chief Executive Officer of IGM Biosciences . " We look forward to announcing a recommended Phase 2 dose for IGM - 2323 , presenting initial dose escalation data from the Phase 1 trial of IGM - 8444 , initiating a Phase 1 trial for IGM - 6268 and filing an IND for IGM - 7354 this year . " Phase 1 dose escalation completed ; dose expansion continues . IGM continues to advance the clinical development of IGM - 2323 , the Company's IgM - based CD20 x CD3 bispecific antibody , for the treatment of non - Hodgkin's lymphoma ( NHL ) . The Company cleared its highest planned dose escalation cohort , a top dose of 1000 mg , without a dose limiting toxicity , and is currently treating additional patients in four Phase 1 dose cohorts with top doses of 100 mg , 300 mg , 600 mg and 1000 mg , respectively . IGM expects to select a recommended Phase 2 dose in 2021 . Additional dose cohorts cleared in Phase 1. IGM continues to advance the clinical development of IGM - 8444 , the Company's IgM Death Receptor 5 ( DR5 ) agonist , for the treatment of a potentially broad range of solid tumors and hematologic malignancies . IGM has cleared its third dose cohort ( 3 mg / kg ) of the single - agent portion of its Phase 1 clinical study and is currently treating patients in its highest dose escalation cohort ( 10 mg / kg ) with every two - week single